Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Alvesco; Alvesco HFA; BTR-15; BTR-15K; BY 9010; Ciclesonide DPI; Ciclesonide I.S.; Ciclesonide pMDI; EL 876; Omnair; Omnaris; Omnaris HFA; RPR 251526; TBN-15; XRP 1526; Zetonna

Latest Information Update: 14 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nycomed
  • Developer Sunovion Pharmaceuticals; Takeda; Takeda Pharmaceuticals International GmbH; Teijin Pharma
  • Class Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis; Asthma; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 06 Nov 2018 Covis Pharma acquires the market rights for ciclesonide outside the US and the US royalties from AstraZeneca
  • 24 Jun 2018 Biomarkers information updated
  • 13 Jul 2017 Covis Pharma acquires US market rights of ciclesonide from Sunovion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top